- Home
- ZIM vs NAMS Comparison
ZIM vs NAMS Comparison
Compare ZIM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIM | NAMS |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | Israel | Netherlands |
| Employees | N/A | 100 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZIM | NAMS |
|---|---|---|
| Price | $26.71 | $34.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $19.26 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.5M | 811.1K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.33 | $15.82 |
| 52 Week High | $29.97 | $42.00 |
Technical Indicators
Market Signals| Indicator | ZIM | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 55.01 |
| Support Level | $25.77 | $29.73 |
| Resistance Level | $26.88 | $37.43 |
| Average True Range (ATR) | 0.47 | 1.77 |
| MACD | -0.01 | 0.38 |
| Stochastic Oscillator | 77.48 | 64.34 |
Price Performance
Historical ComparisonAbout ZIM ZIM Integrated Shipping Services Ltd.
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.